Table 1 Baseline of training set and validation set
Variables | Training set (n = 77) | Validation set (n = 31) | P |
|---|---|---|---|
Age | 52.12 ± 9.97 | 51.03 ± 9.70 | 0.607 |
Menstruation | |||
 Premenopause | 34 (44%) | 16 (52%) | 0.572 |
 Menopause | 43 (56%) | 15 (48%) |  |
T stage | |||
 II | 15 (19%) | 3 (10%) | 0.458 |
 III | 41 (53%) | 18 (58%) |  |
 IV | 21 (27%) | 10 (32%) |  |
N stage | |||
 0 | 11 (14%) | 2 (6%) | 0.322 |
 I | 54 (70%) | 20 (65%) |  |
 II | 3 (4%) | 3 (10%) |  |
 III | 9 (12%) | 6 (19%) |  |
BMI | 23.96 ± 3.40 | 22.64 ± 2.49 | 0.052 |
ER | |||
 ≥10% | 40 (52%) | 15 (48%) | 0.738 |
 < 10% | 37 (48%) | 16 (52%) |  |
PR | |||
 ≥10% | 39 (51%) | 20 (65%) | 0.238 |
 < 10% | 36 (47%) | 11 (35%) |  |
HER2 | |||
 Positive | 34 (44%) | 11 (35%) | 0.408 |
 Negative | 43 (56%) | 20 (65%) |  |
Ki67 (%) | 43.64 ± 20.69 | 39.84 ± 19.39 | 0.382 |
GNRHa | |||
 Yes | 20 (26%) | 9 (29%) | 0.812 |
 No | 57 (74%) | 22 (71%) |  |
CARMN expression | |||
 High | 61 (79%) | 21 (68%) | 0.207 |
 Low | 16 (21%) | 10 (32%) |  |
NAC Response | |||
 Complete response | 47 (61%) | 15 (48%) | 0.284 |
 Partial response | 30 (39%) | 16 (52%) |  |